MCID: TNG003
MIFTS: 57

Tongue Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tongue Cancer

MalaCards integrated aliases for Tongue Cancer:

Name: Tongue Cancer 12 53 55 15
Tongue Carcinoma 53 55 72
Malignant Neoplasm of Base of Tongue 12 33
Malignant Neoplasm of Tongue 12 72
Tongue Neoplasms 44 72
Malignant Neoplasm of Tip and/or Lateral Border of Tongue 12
Malignant Neoplasm of Tip and Lateral Border of Tongue 12
Malignant Neoplasm of Tongue, Tip and Lateral Border 12
Malignant Neoplasm of Anterior Two-Thirds of Tongue 12
Malignant Tumor of Anterior Two-Thirds of Tongue 12
Malignant Neoplasm of Junctional Zone of Tongue 12
Malignant Neoplasm of Ventral Surface of Tongue 12
Malignant Neoplasm of Dorsal Surface of Tongue 12
Malignant Neoplasm of Anterior 2/3 of Tongue 12
Malignant Neoplasm of Ventral Tongue Surface 12
Malignant Neoplasm of Mobile Part of Tongue 12
Malignant Neoplasm of Other Sites of Tongue 12
Malignant Neoplasm of Fixed Part of Tongue 12
Malignant Tumor of Mobile Part of Tongue 12
Malignant Neoplasm of Border of Tongue 12
Malignant Neoplasm of Dorsum of Tongue 12
Malignant Neoplasm of Lingual Tonsil 12
Malignant Neoplasm of Dorsal Tongue 12
Malignant Tumor of Posterior Tongue 12
Malignant Tumor of Base of Tongue 12
Malignant Tumor of Lingual Tonsil 12
Malignant Tumor of Tongue 12
Tongue Neoplasm Malignant 12
Tongue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:8649
MeSH 44 D014062
NCIt 50 C3524 C9345
UMLS 72 C0040411 C0153349 C0153350 more

Summaries for Tongue Cancer

MalaCards based summary : Tongue Cancer, also known as tongue carcinoma, is related to tonsil cancer and oropharynx cancer, and has symptoms including glossalgia An important gene associated with Tongue Cancer is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Nicotine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and tonsil, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Tongue Cancer

Diseases related to Tongue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 tonsil cancer 30.7 TP53 CDKN2A CDH1
2 oropharynx cancer 30.3 TP53 CDKN2A CDH1 CCND1
3 in situ carcinoma 30.3 TP53 CDKN2A CDH1
4 periodontitis 30.2 MMP9 MMP8 MMP2
5 papilloma 30.2 TP53 CDKN2A CDKN1A CCND1
6 tonsil squamous cell carcinoma 30.2 CDKN2A CCND1
7 oral leukoplakia 30.0 TP53 CDKN2A CCND1
8 keratinizing squamous cell carcinoma 29.8 TP53 CDKN2A
9 oral cancer 29.7 TP53 MMP9 MMP2 CDKN2A CDH1 CCND1
10 renal cell carcinoma, nonpapillary 29.7 MMP9 MMP2 MALAT1 CDH1
11 lynch syndrome 29.6 TP53 CTNNB1 CDKN2A CCND1
12 adenoid cystic carcinoma 29.6 TP53 NOTCH1 CTNNB1 CDH1 CCND1
13 lymphoma, non-hodgkin, familial 29.4 TP53 NOTCH1 CCND1 CASP3
14 tongue disease 29.1 VEGFC TP53 MMP2 FAM168A CTNNB1 CDKN2A
15 larynx cancer 29.1 TP53 MMP2 FAM3D-AS1 CDKN2A CCND1
16 tongue squamous cell carcinoma 28.5 VEGFC TP53 NOTCH1 MMP9 MMP2 MALAT1
17 squamous cell carcinoma 28.3 TP53 NOTCH1 MMP2 MALAT1 CTNNB1 CDKN2A
18 nasopharyngeal carcinoma 28.0 VEGFC TP53 MMP9 MALAT1 CDKN2A CDH1
19 bladder cancer 27.9 TP53 MMP9 MMP2 MALAT1 CDKN2A CDKN1A
20 hepatocellular carcinoma 27.5 TP53 MMP9 MMP2 MALAT1 CTNNB1 CDKN2A
21 squamous cell carcinoma, head and neck 27.2 VEGFC TP53 MMP9 MMP2 FAM3D-AS1 CTNNB1
22 gastric cancer 27.1 VEGFC TP53 MMP9 MMP2 MALAT1 CTNNB1
23 lung cancer susceptibility 3 26.8 VEGFC TP53 MMP9 MMP2 MALAT1 CTNNB1
24 esophageal cancer 26.1 VEGFC TP53 MMP9 MMP2 MALAT1 CTNNB1
25 colorectal cancer 26.0 VEGFC TP53 MMP9 MMP2 MALAT1 CTNNB1
26 adult hepatocellular carcinoma 10.7 TP53 CTNNB1
27 cerebral convexity meningioma 10.7 TP53 CDH1
28 invasive bladder transitional cell carcinoma 10.7 TP53 NOTCH1 CDKN1A
29 extracranial arteriovenous malformation 10.7 MMP9 MMP2
30 focal myositis 10.6 MMP9 MMP2
31 splenic diffuse red pulp small b-cell lymphoma 10.6 TP53 NOTCH1
32 actinic cheilitis 10.6 TP53 CDKN1A
33 villous adenocarcinoma 10.6 MMP9 MMP2
34 vulvar intraepithelial neoplasia 10.6 TP53 MMP2
35 ovary epithelial cancer 10.6 TP53 MMP2 CDH1
36 malignant ovarian surface epithelial-stromal neoplasm 10.6 TP53 MMP2 CDH1
37 ovarian cancer 1 10.6 TP53 MMP2 CDH1
38 lentigo maligna melanoma 10.6 MMP9 MMP2
39 spastic entropion 10.6 MMP9 MMP2
40 lobular neoplasia 10.6 PRLR CTNNB1 CDH1
41 amaurosis fugax 10.6 MMP9 MMP8
42 embryonal sarcoma 10.6 TP53 MALAT1 CTNNB1
43 colorectal adenocarcinoma 10.6 TP53 CTNNB1 CDH1
44 psammomatous meningioma 10.5 MMP9 MMP2 CTNNB1
45 intrahepatic cholangiocarcinoma 10.5 TP53 CTNNB1 CDH1
46 transitional cell carcinoma 10.5 TP53 CDKN2A CDH1
47 suppressor of tumorigenicity 3 10.5 TP53 CDKN2A CDKN1A
48 uterine carcinosarcoma 10.5 TP53 CTNNB1 CDH1
49 large intestine adenocarcinoma 10.5 CTNNB1 CDH1
50 adenomyosis 10.5 MMP9 MMP2 CDH1

Comorbidity relations with Tongue Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Tongue Cancer:



Diseases related to Tongue Cancer

Symptoms & Phenotypes for Tongue Cancer

UMLS symptoms related to Tongue Cancer:


glossalgia

MGI Mouse Phenotypes related to Tongue Cancer:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
2 homeostasis/metabolism MP:0005376 10.34 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
3 cellular MP:0005384 10.31 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
4 growth/size/body region MP:0005378 10.29 CASP3 CCND1 CDH1 CDH2 CDKN1A CDKN2A
5 immune system MP:0005387 10.26 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
6 digestive/alimentary MP:0005381 10.2 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
7 endocrine/exocrine gland MP:0005379 10.18 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
8 integument MP:0010771 10.16 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
9 embryo MP:0005380 10.14 CDH1 CDH2 CDKN1A CDKN2A CTNNB1 NOTCH1
10 neoplasm MP:0002006 10.14 CCND1 CDH1 CDKN1A CDKN2A CTNNB1 MMP2
11 nervous system MP:0003631 10.11 CASP3 CCND1 CDH2 CDKN1A CDKN2A CTNNB1
12 craniofacial MP:0005382 10.1 CASP3 CCND1 CDKN1A CTNNB1 MMP2 NOTCH1
13 muscle MP:0005369 10.09 CASP3 CDH2 CDKN1A CDKN2A CTNNB1 MMP2
14 reproductive system MP:0005389 9.91 CASP3 CCND1 CDH1 CDKN1A CDKN2A CTNNB1
15 respiratory system MP:0005388 9.81 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP2
16 pigmentation MP:0001186 9.72 CASP3 CDKN2A CTNNB1 NOTCH1 TP53
17 skeleton MP:0005390 9.65 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP2
18 vision/eye MP:0005391 9.32 CASP3 CCND1 CDKN1A CDKN2A CTNNB1 MMP2

Drugs & Therapeutics for Tongue Cancer

Drugs for Tongue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
tannic acid Approved Phase 4 1401-55-4
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
10
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
11
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
12 Neurotransmitter Agents Phase 4
13 Central Nervous System Stimulants Phase 4
14 Nicotinic Agonists Phase 4
15 Cholinergic Agents Phase 4
16 Autonomic Agents Phase 4
17 Anesthetics Phase 4
18 Central Nervous System Depressants Phase 4
19 Analgesics Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Peripheral Nervous System Agents Phase 4
22 Hypnotics and Sedatives Phase 4
23 Anesthetics, Local Phase 4
24 Anesthetics, General Phase 4
25 Platelet Aggregation Inhibitors Phase 4
26 Anesthetics, Intravenous Phase 4
27 Anesthetics, Inhalation Phase 4
28
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
29
Promethazine Approved, Investigational Phase 3 60-87-7 4927
30
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
31
Histamine Approved, Investigational Phase 3 51-45-6 774
32
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
33
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
34
Metformin Approved Phase 3 657-24-9 4091 14219
35
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
36 Antiviral Agents Phase 3
37 Anti-HIV Agents Phase 3
38 Anti-Retroviral Agents Phase 3
39 Interleukin-2 Phase 3
40 Vaccines Phase 3
41 Antidepressive Agents Phase 3
42 Histamine Antagonists Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Psychotropic Drugs Phase 3
45 Antidepressive Agents, Tricyclic Phase 3
46 Muscarinic Agonists Phase 2, Phase 3
47 Hypoglycemic Agents Phase 3
48
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
49
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
50
Indinavir Approved Phase 2 150378-17-9 5362440

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
3 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
4 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
5 Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Completed NCT00050388 Phase 3
6 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
7 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
8 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
9 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
10 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
11 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
12 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
13 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Unknown status NCT02849379 Phase 1, Phase 2
14 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Unknown status NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
15 Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
16 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
17 A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
18 A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
19 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
20 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
21 A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer Completed NCT01195922 Phase 1, Phase 2 Sirolimus
22 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
23 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
24 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
25 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
26 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
27 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
28 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
29 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
30 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
31 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
32 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
33 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
34 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
35 Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
36 Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection Completed NCT00875849 Phase 2 cisplatin
37 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
38 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
39 A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers Completed NCT00423930 Phase 2 cisplatin
40 A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma Completed NCT00851877 Phase 1, Phase 2 Cisplatin;Nab-Paclitaxel
41 Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
42 A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
43 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
44 Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
45 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
46 Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
47 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
48 A Phase II Study of Tongue Conservation Surgery for Advanced Oral Tongue Cancer: Induction Chemotherapy, Followed by Tongue Conservation Surgery and Postoperative Chemoradoitherapy Terminated NCT03161548 Phase 2 Induction chemotherapy
49 DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Terminated NCT01313390 Phase 1, Phase 2 docetaxel;everolimus
50 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules

Search NIH Clinical Center for Tongue Cancer

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Cancer

Anatomical Context for Tongue Cancer

MalaCards organs/tissues related to Tongue Cancer:

41
Tongue, Lymph Node, Tonsil, Lung, Endothelial, Brain, Bone

Publications for Tongue Cancer

Articles related to Tongue Cancer:

(show top 50) (show all 1949)
# Title Authors PMID Year
1
Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. 9 38
19331169 2009
2
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. 9 38
18253113 2008
3
Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. 9 38
17611661 2007
4
NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. 9 38
17005413 2006
5
Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma. 9 38
16767431 2006
6
Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. 9 38
16331606 2006
7
[Effects of arsenic trioxideon the cell apoptosis and hTERT mRNA of human tongue cancer cells]. 9 38
16285558 2005
8
The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. 9 38
15289890 2004
9
Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. 9 38
14730689 2004
10
Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. 9 38
14977084 2004
11
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. 9 38
12454097 2002
12
Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. 9 38
11900224 2002
13
A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. 9 38
11206273 2001
14
Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. 9 38
11315101 2000
15
p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years. 9 38
10645402 1999
16
Tenascin: growth and adhesion modulation--extracellular matrix degrading function: an in vitro study. 9 38
8736172 1996
17
Expression of the cell-cell adhesion molecule E-cadherin in tongue carcinoma cell lines. 9 38
7829949 1994
18
Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study. 9 38
8181582 1994
19
Esophageal cancer related gene-4 inhibits the migration and proliferation of oral squamous cell carcinoma through BC200 lncRNA/MMP-9 and -13 signaling pathway. 38
31152845 2019
20
The effect of depth of invasion on node negative tongue cancer staging. 38
31046152 2019
21
Swallowing function in advanced tongue cancer patients before and after bilateral neck dissection following superselective intra-arterial chemoradiotherapy for organ preservation: a case-control study. 38
30484199 2019
22
Recategorization of tumor stage in patients with node-negative oral tongue cancer: Impact of the eighth edition American Joint Committee staging system. 38
31025799 2019
23
Machine learning application for prediction of locoregional recurrences in early oral tongue cancer: a Web-based prognostic tool. 38
31422502 2019
24
The role of the T-N tract in advanced stage tongue cancer. 38
30942940 2019
25
Application of "parachute" technique for free flap reconstruction in advanced tongue cancer after ablation without lip-jaw splitting: A retrospective case study. 38
31415367 2019
26
Assessment of Tumor-infiltrating Lymphocytes Predicts the Behavior of Early-stage Oral Tongue Cancer. 38
31290758 2019
27
Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma. 38
31399243 2019
28
Suppression of the long non-coding RNA MALAT-1 impairs the growth and migration of human tongue squamous cell carcinoma SCC4 cells. 38
31360193 2019
29
KRAS mutations in tongue squamous cell carcinoma. 38
31066593 2019
30
The influence of lymph node ratio on survival and disease recurrence in squamous cell carcinoma of the tongue. 38
30738712 2019
31
[Proportion and role of CD45+ erythroid progenitor cells in patients with tongue cancer metastasis]. 38
31288323 2019
32
Reliability of MRI-Derived Depth of Invasion of Oral Tongue Cancer. 38
30268718 2019
33
Tongue cancer: A discrete oral cavity subsite. 38
31272801 2019
34
Incidental finding of tongue cancer in a PET scan: A fusion of anatomic and metabolic imaging. 38
31351902 2019
35
A 3D-printed patient-specific applicator guide for use in high-dose-rate interstitial brachytherapy for tongue cancer: a phantom study. 38
31170698 2019
36
Crossing muscle fibers of the human tongue resolved in vivo using constrained spherical deconvolution. 38
30648339 2019
37
PCR-based zebrafish model for personalised medicine in head and neck cancer. 38
31331338 2019
38
In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients. 38
31356815 2019
39
Pharyngeal reconstruction by anterolateral thigh flap with vastus lateralis muscle transfer for effective swallowing after total glossolaryngectomy: A case report. 38
30861231 2019
40
FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathway. 38
31291942 2019
41
Melatonin and (-)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer. 38
31331008 2019
42
Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis. 38
30408182 2019
43
Assessment of the Rate of Skip Metastasis to Neck Level IV in Patients With Clinically Node-Negative Neck Oral Cavity Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. 38
31070693 2019
44
Effect of adriamycin combined with metformin on biological function of human tongue cancer SSC-15 cells. 38
31186791 2019
45
Changes in incidence and prevalence of human papillomavirus in tonsillar and base of tongue cancer during 2000-2016 in the Stockholm region and Sweden. 38
30584688 2019
46
Molecular profile of tongue cancer in an 18-year-old female patient with no recognizable risk factor. 38
31236464 2019
47
Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis. 38
31208348 2019
48
LncRNA UCA1/miR-124 axis modulates TGFβ1-induced epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling. 38
30635938 2019
49
Sentinel Lymph Node Biopsy Using Preoperative Computed Tomographic Lymphography and Intraoperative Indocyanine Green Fluorescence Imaging in Patients With Localized Tongue Cancer. 38
31246253 2019
50
Three-Dimensional Tumor Margin Demarcation Using the Hybrid Tracer Indocyanine Green-99mTc-Nanocolloid: A Proof-of-Concept Study in Tongue Cancer Patients Scheduled for Sentinel Node Biopsy. 38
30504140 2019

Variations for Tongue Cancer

Expression for Tongue Cancer

Search GEO for disease gene expression data for Tongue Cancer.

Pathways for Tongue Cancer

Pathways related to Tongue Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VEGFC TP53 NOTCH1 CTNNB1 CDKN2A CDKN1A
2
Show member pathways
13.76 VEGFC TP53 NOTCH1 MMP9 MMP8 MMP2
3
Show member pathways
13.39 TP53 PRLR MMP9 MMP2 CDKN1A CCND1
4
Show member pathways
12.99 TP53 MMP9 CTNNB1 CDKN2A CDKN1A CCND1
5
Show member pathways
12.95 VEGFC TP53 PRLR NOTCH1 CTNNB1 CDKN1A
6
Show member pathways
12.8 TP53 MMP9 CTNNB1 CDKN2A CDKN1A CDH1
7
Show member pathways
12.78 MMP9 MMP8 MMP2 CDH1 CASP3
8
Show member pathways
12.76 TP53 NOTCH1 CTNNB1 CDKN2A CDKN1A CDH1
9
Show member pathways
12.6 TP53 NOTCH1 MMP9 MMP2 CDKN2A CDKN1A
10 12.46 TP53 CTNNB1 CDH2 CDH1 CCND1
11
Show member pathways
12.41 TP53 CDKN2A CDKN1A CCND1 CASP3
12 12.4 TP53 CTNNB1 CDKN2A CDKN1A CCND1
13 12.39 TP53 CDKN2A CDKN1A CDH1 CCND1
14
Show member pathways
12.38 TP53 CDKN2A CDKN1A CCND1
15 12.35 TP53 NOTCH1 MMP9 CDKN2A CDKN1A CCND1
16 12.32 TP53 CDKN2A CDKN1A CCND1 CASP3
17 12.29 TP53 MMP9 CDKN1A BMI1
18
Show member pathways
12.29 TP53 CDKN1A CCND1 CASP3
19
Show member pathways
12.23 TP53 CDKN1A CCND1 CASP3
20 12.21 TP53 CDKN2A CDKN1A CCND1
21 12.18 TP53 MMP9 MMP2 CTNNB1 CDKN1A CCND1
22 12.17 TP53 CDKN1A CCND1 CASP3
23
Show member pathways
12.16 MMP2 CTNNB1 CDKN1A CCND1
24 12.16 TP53 CTNNB1 CDH1 CCND1 CASP3
25 12.13 TP53 MMP9 MMP2 CTNNB1
26 12.12 NOTCH1 CTNNB1 CDH2 CDH1 CASP3
27 12.09 VEGFC TP53 NOTCH1 MMP9 MMP2 CTNNB1
28 12.07 TP53 MMP2 CTNNB1 CDKN2A CDKN1A
29 12.05 TP53 MMP9 CCND1 CASP3
30 12.05 TP53 NOTCH1 CTNNB1 CCND1
31
Show member pathways
12.02 TP53 CTNNB1 CDH2 CDH1 CCND1
32 12.02 MMP9 MMP2 CTNNB1 CDH2 CDH1
33 11.99 TP53 CDKN2A CDKN1A BMI1
34 11.98 TP53 CTNNB1 CDKN2A CDKN1A CCND1
35 11.98 TP53 MMP9 MMP2 CTNNB1 CDKN1A CDH1
36 11.96 NOTCH1 CTNNB1 CDH2 CDH1
37 11.95 VEGFC MMP2 CCND1 CASP3
38 11.95 TP53 MMP9 MMP2 CDKN1A CCND1
39 11.92 TP53 CTNNB1 CDKN2A CDKN1A CCND1
40 11.9 TP53 CDKN1A CCND1 CASP3
41 11.88 CTNNB1 CDKN1A CCND1
42 11.87 VEGFC NOTCH1 MMP9 MMP2
43 11.86 TP53 CDKN1A CCND1
44 11.82 TP53 MMP9 BMI1
45 11.78 NOTCH1 CTNNB1 CDKN1A CDH2
46 11.77 TP53 CDKN2A CDKN1A CASP3
47 11.73 TP53 MMP2 CTNNB1 CDKN2A CDKN1A
48 11.73 MMP9 MMP2 CTNNB1 CDH1 CCND1
49 11.72 MMP9 MMP2 CASP3
50 11.71 MMP9 MMP2 CASP3

GO Terms for Tongue Cancer

Cellular components related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction GO:0005912 9.43 NOTCH1 CTNNB1 CDH2
2 fascia adherens GO:0005916 9.16 CTNNB1 CDH2
3 flotillin complex GO:0016600 8.96 CTNNB1 CDH1
4 catenin complex GO:0016342 8.8 CTNNB1 CDH2 CDH1

Biological processes related to Tongue Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 TP53 NOTCH1 MMP8 CTNNB1 CDKN2A
2 negative regulation of apoptotic process GO:0043066 9.99 TP53 PRLR MMP9 CTNNB1 CDKN1A CASP3
3 G1/S transition of mitotic cell cycle GO:0000082 9.82 CDKN2A CDKN1A CCND1
4 Ras protein signal transduction GO:0007265 9.8 TP53 CDKN2A CDKN1A
5 cell cycle arrest GO:0007050 9.8 TP53 NOTCH1 CDKN2A CDKN1A
6 response to glucocorticoid GO:0051384 9.79 CDKN1A CCND1 CASP3
7 extracellular matrix disassembly GO:0022617 9.76 MMP9 MMP8 MMP2
8 positive regulation of apoptotic process GO:0043065 9.73 TP53 NOTCH1 MMP9 CTNNB1 CDKN2A CASP3
9 animal organ regeneration GO:0031100 9.72 NOTCH1 CDKN1A CCND1
10 adherens junction organization GO:0034332 9.71 CTNNB1 CDH2 CDH1
11 response to organic substance GO:0010033 9.71 CDKN1A CDH1 CCND1 CASP3
12 embryo implantation GO:0007566 9.7 PRLR MMP9 MMP2
13 collagen catabolic process GO:0030574 9.65 MMP9 MMP8 MMP2
14 negative regulation of oligodendrocyte differentiation GO:0048715 9.64 NOTCH1 CTNNB1
15 morphogenesis of embryonic epithelium GO:0016331 9.63 VEGFC CTNNB1
16 somatic stem cell division GO:0048103 9.63 NOTCH1 CDKN2A
17 endodermal cell differentiation GO:0035987 9.63 MMP9 MMP8 MMP2
18 mitotic G1 DNA damage checkpoint GO:0031571 9.61 TP53 CCND1
19 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.61 CDKN2A CDKN1A CASP3
20 entry of bacterium into host cell GO:0035635 9.6 CTNNB1 CDH1
21 signal transduction by p53 class mediator GO:0072331 9.58 TP53 CDKN1A
22 regulation of neuroinflammatory response GO:0150077 9.57 MMP9 MMP8
23 cellular response to indole-3-methanol GO:0071681 9.56 CTNNB1 CDH1
24 positive regulation of neuroblast proliferation GO:0002052 9.54 VEGFC NOTCH1 CTNNB1
25 response to X-ray GO:0010165 9.5 CDKN1A CCND1 CASP3
26 response to drug GO:0042493 9.43 VEGFC CTNNB1 CDKN1A CDH1 CCND1 CASP3
27 replicative senescence GO:0090399 9.33 TP53 CDKN2A CDKN1A
28 cytokine-mediated signaling pathway GO:0019221 9.1 TP53 MMP9 MMP2 CDKN1A CCND1 CASP3
29 negative regulation of cell proliferation GO:0008285 10.01 TP53 NOTCH1 CTNNB1 CDKN2A CDKN1A

Molecular functions related to Tongue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.65 TP53 NOTCH1 CTNNB1 CDH2 CCND1
2 protein phosphatase binding GO:0019903 9.54 TP53 CTNNB1 CDH2
3 protein kinase binding GO:0019901 9.43 TP53 CTNNB1 CDKN2A CDKN1A CDH2 CCND1
4 gamma-catenin binding GO:0045295 9.4 CDH2 CDH1
5 disordered domain specific binding GO:0097718 9.33 TP53 CTNNB1 CDKN2A
6 alpha-catenin binding GO:0045294 9.32 CTNNB1 CDH2
7 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN2A CDKN1A CASP3

Sources for Tongue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....